His scientific interests lie mostly in Tuberculosis, Surgery, Immunology, Mycobacterium tuberculosis and Internal medicine. Peter R. Donald interconnects Pharmacokinetics and Pediatrics in the investigation of issues within Tuberculosis. His Surgery research includes themes of Pulmonary tuberculosis, Disease and Intensive care medicine.
He combines subjects such as Antibiotics, Rifampicin and Dose–response relationship with his study of Immunology. His Mycobacterium tuberculosis study integrates concerns from other disciplines, such as Miliary tuberculosis and Epidemiology. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Delamanid and Standard treatment.
Tuberculosis, Pediatrics, Internal medicine, Surgery and Isoniazid are his primary areas of study. The Tuberculosis study combines topics in areas such as Pharmacokinetics, Pharmacology and Immunology. In his study, Chemoprophylaxis is strongly linked to Incidence, which falls under the umbrella field of Pediatrics.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Pyrazinamide and Endocrinology. His studies in Pyrazinamide integrate themes in fields like Ethionamide and Ethambutol. His Isoniazid research is multidisciplinary, relying on both Antibacterial agent, Rifampicin and Drug resistance.
His primary scientific interests are in Tuberculosis, Pharmacokinetics, Pediatrics, Pharmacology and Internal medicine. His biological study spans a wide range of topics, including Adverse effect and Immunology. His Pediatrics study focuses on Tuberculous meningitis in particular.
Peter R. Donald has included themes like Multiple drug resistance and Isoniazid in his Pharmacology study. His work deals with themes such as Gastroenterology, Pyrazinamide, Moxifloxacin and Ethambutol, which intersect with Internal medicine. His Standard treatment research is multidisciplinary, incorporating elements of Antibacterial agent and Surgery.
Peter R. Donald focuses on Tuberculosis, Pharmacology, Internal medicine, Pyrazinamide and Pediatrics. Peter R. Donald studies Bedaquiline, a branch of Tuberculosis. His studies deal with areas such as Sputum, Isoniazid and Mycobacterium tuberculosis as well as Pharmacology.
His research in Internal medicine intersects with topics in Moxifloxacin, Surgery and Ethambutol. Rifampicin covers he research in Pyrazinamide. His work carried out in the field of Pediatrics brings together such families of science as MEDLINE, Disease, Severity of illness, Drug and Malnutrition.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.
B J Marais;R P Gie;H S Schaaf;A C Hesseling.
International Journal of Tuberculosis and Lung Disease (2004)
Tuberculous meningitis: a uniform case definition for use in clinical research
Suzaan Marais;Guy Thwaites;Johan F Schoeman;M Estée Török.
Lancet Infectious Diseases (2010)
Childhood pulmonary tuberculosis: old wisdom and new challenges.
Ben J. Marais;Robert P. Gie;H. Simon Schaaf;Nulda Beyers.
American Journal of Respiratory and Critical Care Medicine (2006)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H Diacon;Rodney Dawson;Florian von Groote-Bidlingmaier;Gregory Symons.
The Lancet (2012)
Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance
A. H. Diacon;P. R. Donald;A. Pym;M. Grobusch.
Antimicrobial Agents and Chemotherapy (2012)
Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis.
J F Schoeman;L E Van Zyl;J A Laubscher;P R Donald.
Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis
R. Rustomjee;A. H. Diacon;J. Allen;A. Venter.
Antimicrobial Agents and Chemotherapy (2008)
Twenty Years of Pediatric Tuberculous Meningitis: A Retrospective Cohort Study in the Western Cape of South Africa
G. T. J. van Well;B. F. Paes;C. B. Terwee;P. Springer.
Evaluation of Young Children in Contact With Adult Multidrug-Resistant Pulmonary Tuberculosis: A 30-Month Follow-up
H. Simon Schaaf;Robert P. Gie;Magdalene Kennedy;Nulda Beyers.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson;Andreas H Diacon;Daniel Everitt;Christo van Niekerk.
The Lancet (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: